JP2022539753A - ガンマデルタｔ細胞を阻害する、または活性化させる方法 - Google Patents

ガンマデルタｔ細胞を阻害する、または活性化させる方法 Download PDF

Info

Publication number
JP2022539753A
JP2022539753A JP2021577332A JP2021577332A JP2022539753A JP 2022539753 A JP2022539753 A JP 2022539753A JP 2021577332 A JP2021577332 A JP 2021577332A JP 2021577332 A JP2021577332 A JP 2021577332A JP 2022539753 A JP2022539753 A JP 2022539753A
Authority
JP
Japan
Prior art keywords
btn2a1
cells
btn3a1
antagonist
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021577332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539753A5 (https=
Inventor
ベーレン アンドレアス
セボン ジョナサン
リゴー コータル マーク
サミュエル フルフォード トーマス
イアン ゴドフリー デイル
ハメット アンドリュー
オストロウスカ シモン
パノウシス コン
ピーター ウルドリッチ アダム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902308A external-priority patent/AU2019902308A0/en
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of JP2022539753A publication Critical patent/JP2022539753A/ja
Publication of JP2022539753A5 publication Critical patent/JP2022539753A5/ja
Priority to JP2025013162A priority Critical patent/JP2025090566A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2021577332A 2019-06-28 2020-06-26 ガンマデルタｔ細胞を阻害する、または活性化させる方法 Pending JP2022539753A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025013162A JP2025090566A (ja) 2019-06-28 2025-01-29 ガンマデルタｔ細胞を阻害する、または活性化させる方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2019902308A AU2019902308A0 (en) 2019-06-28 Method of inhibiting or activating gamma delta t cells
AU2019902308 2019-06-28
AU2019904771A AU2019904771A0 (en) 2019-12-17 Method of inhibiting or activating gamma delta t cells
AU2019904773 2019-12-17
AU2019904771 2019-12-17
AU2019904773A AU2019904773A0 (en) 2019-12-17 Method of inhibiting or activating gamma delta t cells
PCT/AU2020/050662 WO2020257871A1 (en) 2019-06-28 2020-06-26 Method of inhibiting or activating gamma delta t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025013162A Division JP2025090566A (ja) 2019-06-28 2025-01-29 ガンマデルタｔ細胞を阻害する、または活性化させる方法

Publications (2)

Publication Number Publication Date
JP2022539753A true JP2022539753A (ja) 2022-09-13
JP2022539753A5 JP2022539753A5 (https=) 2023-07-04

Family

ID=74059614

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577332A Pending JP2022539753A (ja) 2019-06-28 2020-06-26 ガンマデルタｔ細胞を阻害する、または活性化させる方法
JP2025013162A Pending JP2025090566A (ja) 2019-06-28 2025-01-29 ガンマデルタｔ細胞を阻害する、または活性化させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025013162A Pending JP2025090566A (ja) 2019-06-28 2025-01-29 ガンマデルタｔ細胞を阻害する、または活性化させる方法

Country Status (8)

Country Link
US (1) US20220273713A1 (https=)
EP (1) EP3990496A4 (https=)
JP (2) JP2022539753A (https=)
KR (1) KR20220100567A (https=)
CN (1) CN114746445A (https=)
AU (1) AU2020301813A1 (https=)
CA (1) CA3144755A1 (https=)
WO (1) WO2020257871A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022109110A1 (en) * 2020-11-19 2022-05-27 Shattuck Labs, Inc. Methods of identifying gamma delta t cell-modulating agents
US20250179144A1 (en) * 2021-12-09 2025-06-05 The University Of Melbourne Modified Butyrophilin and Butyrophilin Complexes
EP4638472A1 (en) * 2022-12-19 2025-10-29 UMC Utrecht Holding B.V. Btn2a1 binding peptide
WO2025031287A1 (zh) * 2023-08-04 2025-02-13 江苏恒瑞医药股份有限公司 Btn3a结合蛋白及其医药用途
WO2025045192A1 (en) * 2023-08-31 2025-03-06 Biosion Inc. Antibodies binding btn3a1 and uses thereof
WO2025064752A1 (en) * 2023-09-20 2025-03-27 La Jolla Institute For Immunology Human anti-sars-cov-2 spike (s) antibodies
WO2025082418A1 (zh) * 2023-10-18 2025-04-24 苏州沙砾生物科技有限公司 一种鉴定靶标的方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019057933A1 (en) * 2017-09-21 2019-03-28 Imcheck Therapeutics Sas ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0717101D0 (en) * 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
JP2016540046A (ja) * 2013-11-29 2016-12-22 シーエスエル、リミテッド ガンの治療方法
EP3827838B1 (en) * 2015-12-16 2023-06-07 The Walter and Eliza Hall Institute of Medical Research Inhibition of cytokine-induced sh2 protein in nk cells
WO2017149394A1 (en) * 2016-02-29 2017-09-08 Ose Immunotherapeutics Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019057933A1 (en) * 2017-09-21 2019-03-28 Imcheck Therapeutics Sas ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF

Also Published As

Publication number Publication date
AU2020301813A1 (en) 2022-01-27
WO2020257871A1 (en) 2020-12-30
KR20220100567A (ko) 2022-07-15
EP3990496A1 (en) 2022-05-04
US20220273713A1 (en) 2022-09-01
JP2025090566A (ja) 2025-06-17
EP3990496A4 (en) 2023-08-09
CA3144755A1 (en) 2020-12-30
CN114746445A (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
JP2022539753A (ja) ガンマデルタｔ細胞を阻害する、または活性化させる方法
JP2021508676A (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
IL271696B2 (en) Agonist antibodies that bind human CD137 and their use
US12286483B2 (en) Method of treating cancer using CD137 antibodies and PD-1 antagonists
JP2019512207A (ja) Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
JP2019534710A (ja) インターロイキン２に結合する抗体およびその使用
JP2021533785A (ja) 共有抗原を標的指向する抗原結合タンパク質
US11919953B2 (en) TIGIT and CD112R blockade
US20210388089A1 (en) Antigen binding agents that bind cd277 and uses thereof
WO2021236638A1 (en) Mageb2 binding constructs
KR20200028447A (ko) 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
US12460004B2 (en) Antibodies that bind CD277 and uses thereof
IL295164A (en) Antibody molecules against lilrb3 and their uses
WO2023137161A1 (en) Triple blockade of tigit, cd112r, and pd-l1
TW202413412A (zh) 在組合療法中能夠結合到ｃｄ２７之結合劑
WO2020033925A9 (en) Antibodies that bind cd277 and uses thereof
HK40031598B (zh) 抗tigit抗体及其作为治疗和诊断的用途
EA046914B1 (ru) Антитела-агонисты, которые связывают cd137 человека, и варианты их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250304